tirzepatide obstructive sleep apnea fda approval 2024 Huge news: has approved Zepbound (tirzepatide- GLP-1/GIP receptor agonist) for the treatment of moderate to severe in adults with obesity. As a cardiologist, this is a huge deal Last week, the FDA approved
Description
As of July 2025, these search trends mark a clear inflection point
Even if you were on the maximum 2.4mg of semaglutide, you start tirzepatide at 2.5mg

Maybe evening would have been better
Every dosing decision becomes simpler with the right tools and the right knowledge behind it
